Why the study?
Does triflusal reduce serious vascular events compared to aspirin or placebo in patients at high risk of vascular events?
Population
5,622 patients at high risk of vascular events pooled from 7 randomized and quasi-randomized trials.
Comparison
Triflusal vs Aspirin or placebo
Design
Meta-analysis, Randomised and quasi-randomised
Follow-up
35 days to 47 months
Authors
Loading...
Triflusal matches aspirin's efficacy against serious vascular events with lower hemorrhagic risk; reinforces its role as a viable alternative for secondary prevention.
Does triflusal reduce serious vascular events compared to aspirin or placebo in patients at high risk of vascular events?
Triflusal shows similar efficacy to aspirin for secondary prevention of serious vascular events but is associated with a significantly lower risk of hemorrhagic complications.
Costa et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: